Ivermectin has an “antiviral effect” against COVID-19, according to a Monday report by Kowa Co. Ltd., a Japanese pharmaceutical company.

The company has been working alongside Kitasato University in Tokyo, according to Reuters, and has declined to provide the outlet with further information on the ongoing testing of the drug’s effectiveness in treating the virus.

Ivermectin’s use as a COVID therapeutic is also being investigated in the U.K., and is currently undergoing a trial run at the University of Oxford, according to the report. Researchers at Oxford also declined to provide Reuters with further comment.